Sponsor-Investigator Trials Provide Avenue For Firms To Expand Device Uses
This article was originally published in The Gray Sheet
Executive Summary
Physician studies of W.L. Gore's Helex septal occluder, used in the closure of atrial septal defects, demonstrate that the device can also close patent foramen ovale (PFO) for prophylaxis of recurrent paradoxical embolism and embolic stroke
You may also be interested in...
FDAMA In Action? ODE Shows Progress On IDE Supplements, Five-Day Notice
The Center for Devices and Radiological Health is addressing industry concerns over FDA's handling of increasing numbers of investigational device exemption supplements and use of the agency's five-day notice program for clinical trial changes
FDAMA In Action? ODE Shows Progress On IDE Supplements, Five-Day Notice
The Center for Devices and Radiological Health is addressing industry concerns over FDA's handling of increasing numbers of investigational device exemption supplements and use of the agency's five-day notice program for clinical trial changes
NMT, AGA Medical Pursue PFO Indication Following Septal Defect Approvals
Nitinol Medical Technologies' CardioSeal approval for ventricular septal defects Dec. 5 paves the way for pursuit of expanded approval to treat the much larger population with patent foramen ovale, the firm says